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Abstract
Background: Type 2 diabetes is characterised by abnormal glucose metabolism, and treatment is aimed at
normalising glycaemia. Outcomes measured in clinical trials should be meaningful to patients, health care professionals
and researchers, yet there is heterogeneity in the outcomes used across trials of glucose-lowering interventions. This
inconsistency affects the ability to compare findings and may mean that the results have little importance to health
care professionals and the patients for whom they care. The SCORE-IT study aims to develop a core outcome set (COS)
for use in all trials of glucose-lowering interventions for people with type 2 diabetes.
Methods/design: This study will involve three key stages in the development of a COS: (1) A list of outcomes will be
identified from multiple sources, specifically registered clinical trials, online patient resources, the qualitative literature
and landmark studies identified by a Study Steering Committee. (2) The list of outcomes will be scored by multiple
stakeholder groups in a two-round online international Delphi survey. (3) The results of the online Delphi will be
summarised and discussed at a face-to-face consensus meeting with representation from all stakeholder groups.
Discussion: The SCORE-IT study aims to develop an internationally relevant set of core outcomes for use in future trials
of glucose-lowering interventions for type 2 diabetes. The use of a COS will improve the consistency of outcomes, allowing
results of studies to be compared and combined and for new effective treatments to made available more quickly.
Trial registration: The COS study, of which this is a part, is registered in the Core Outcome Measures in Effectiveness Trials
(COMET) database, http://www.comet-initiative.org/studies/details/956. Registered January 2017.
Keywords: Core outcome set, Systematic review, Type 2 diabetes
Background
The global prevalence of diabetes was estimated to be
8.8% of adults 20–79 years in 2017, and by 2045 it is
predicted that diabetes will affect 623 million people in
this age bracket, a 48% increase from 2017 [1], with type
2 diabetes accounting for the majority of cases [2, 3].
Whilst prevention of type 2 diabetes is a key focus for
health care [4], it is inevitable that a proportion of those
considered to be at high risk or “pre-diabetic” will go on
to develop type 2 diabetes and require intervention to
normalise their blood glucose [5, 6].
Type 2 diabetes is characterised by abnormal glucose
metabolism brought about by resistance to insulin action
and an inadequate compensatory insulin secretory response
[7, 8]. Treatment of type 2 diabetes ultimately aims to
control glycaemia, by lifestyle changes or pharmacotherapy,
to avoid hyperglycaemia and associated long-term
complications. Pharmacotherapy for type 2 includes a num-
ber of classes of pharmaceutical agents which affect gly-
caemia through varying cellular mechanisms and resulting
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physiological actions [9, 10]. Lifestyle changes focus on
changes to physical activity and dietary intake with body
weight management being the primary focus [11–15].
These methods may also be supplemented with bariatric
surgical intervention [16].
The primary and secondary outcomes used in clinical
trials of glucose-lowering interventions are varied, and
systematic reviews identify inconsistency in the outcomes
measured and reported. Although many trials report
glycated haemoglobin, other measures of glycaemic con-
trol and outcomes relating to hypoglycaemia, mortality,
diabetes-related complications and quality of life are less
frequently reported [3–8]. In a recent systematic review of
open recruiting trials registered with ClinicalTrials.gov, no
single outcome was measured in 100% of the included
studies [17], and this heterogeneity in outcomes may have
an impact on the translatability of trials into benefits for
patients. [18, 19].
The relevance and consistency of trial outcomes may be
improved by the development of a core outcome set
(COS) that represents the minimum set of outcomes that
should be measured and reported in any clinical trial for a
given condition, in this case type 2 diabetes [13–15].
Aims and objective
The aim of this study is to contribute to the development
of an international COS, relevant to glucose-lowering inter-
ventions for use in studies of adults with type 2 diabetes.
The specific study objectives are as follows: to identify
a list of outcomes used in current, open clinical trials
registered on ClinicalTrials.gov together with outcomes
reported in qualitative literature relevant to type 2
diabetes; to prioritise outcomes from the health care
professional perspective; to prioritise outcomes from the
perspective of patients with type 2 diabetes; to prioritise
outcomes from the perspective of researchers in the field
and policy makers; and to integrate the outcomes im-
portant to all stakeholders into a combined COS.
Identifying existing knowledge
A search of the Core Outcome Measures in Effectiveness
Trials (COMET) initiative database (http://www.come-
t-initiative.org/) was completed prior to commencing
this project (on 21 October 2016). No published or on-
going COS for trials involving patients with type 2 dia-
betes without co-morbidity was identified.
Scope of the core outcome set
This COS will be developed for effectiveness trials evaluat-
ing any non-surgical therapeutic intervention for the treat-
ment of hyperglycaemia in adults with type 2 diabetes.
Surgical interventions will not be included, as these
outcomes are captured in an existing COS for bariatric
and metabolic surgery [20]. Type 1 diabetes, gestational
diabetes, type 2 diabetes in children and maturity-onset
diabetes of the young (MODY) are outside the scope of
this COS.
Study oversight
An international Study Steering Committee (SSC) com-
prising three health care professionals, four public con-
tributors and a policy maker with experience in COSs has
been established. The remit of the SSC is to oversee the
SCORE-IT study, provide feedback on the study protocol
and list of outcomes, contribute to the dissemination of
the online Delphi survey and to contribute to the final
consensus meeting and dissemination of the COS.
Methods/design
The COS development process will involve the steps
shown in Fig. 1. Each of these is described below.
Step 1: identification of outcomes
The list of outcomes for use in an online Delphi survey
will be generated from the following sources:
1. A systematic review of open and recruiting trials
registered with ClinicalTrials.gov. The search
strategy and results of this systematic review have
been published elsewhere [17].
2. Identification of additional outcomes from long-term
cardiovascular outcome studies. Guidance released
by the Food and Drug Administration (FDA) required
clinical trials for the treatment of type 2 diabetes to
demonstrate cardiovascular safety of the new treat-
ment by including specific cardiovascular outcomes
[21]. The outcomes described by the FDA will be
reviewed against the outcomes identified from open,
registered trials, and new outcomes will be included in
the initial list of outcomes for round 1 of the Delphi.
Trials initiated in response to the FDA guidance were
long-term follow-up studies that have now been
completed or are nearing completion. As most of
these studies are no longer recruiting, they will not
be identified in the ClinicalTrials.govsearch results.
Instead a list of the key trials that opened between
2008 and 2016 will be provided by the SSC and
outcomes extracted.
3. Health Talk Online is a public website containing
information and patient interviews for a range of
health conditions. The experiences of patients with
type 2 diabetes shared as video clips on Health Talk
Online will be reviewed and potential outcomes
extracted [22]. Only transcripts of patients aged
18 and older without a co-morbidity will be used.
4. Outcomes will be identified from a narrative
synthesis of the qualitative literature. The protocol
for the narrative synthesis and resulting outcomes
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has been submitted for publication separately.
Briefly, a search of the literature in MEDLINE, with
no restrictions on date, will be undertaken. The
search terms, described in Table 1, comprise
empirically tested qualitative methodological filters
designed to identify qualitative research from the
MEDLINE electronic database with maximum
specificity [23]. Abstracts will be screened, and the
full text will be reviewed for articles meeting the
following inclusion criteria: participants are patients
with type 2 diabetes; the focus is type 2 diabetes
and not an associated co-morbidity; and qualitative
methods (interviews and/or focus groups) have
been used.
5. A recent study by Reaney et al. has examined
patient-reported outcome measures (PROMs)
used in phase 3 clinical trials of glucagon-like
peptide 1 (GLP-1) receptor agonists, novel insulins,
sodium-glucose co-transporter 2 (SGLT-2) inhibitors
and dipeptidyl peptidase-4 DPP-4 inhibitors [24]. The
outcome domains in these PROMS will be reviewed
against those identified in sources 1–4 for additional
outcomes.
6. The Cochrane Database of Systematic Reviews
will be searched for “type 2 diabetes” in the title,
abstract and keywords. Eligible reviews will be
those of glucose-lowering interventions for type
2 diabetes. The outcomes used in the included
Cochrane reviews will be extracted and compared
against the list of outcomes identified in sources
1–4 for additional outcomes.
7. The EUropean Best Information through Regional
Outcomes in Diabetes (EUBIROD) project’s BIRO
common data set for clinical practice will be
reviewed for potentially relevant outcomes that
have not been identified from the systematic
review or other sources [25].
Review of the final outcome list
The list of outcomes from all sources will be reviewed by
NLH and JW to group like outcomes together and cat-
egorise each outcome according to a 38-item taxonomy
[26]. The outcomes list will then be reviewed by members
of the SSC to ensure that outcomes have been grouped
appropriately, the outcome description is clear and that
there are no duplications within the outcomes. The SSC
will also take into consideration the number of outcomes
and may request that outcomes be further condensed and
combined or that outcomes be removed if measured in a
single or small number of studies or if they are deemed to
be irrelevant to glucose-lowering interventions. This
approach will ensure that the number of outcomes to be
scored by participants of the online Delphi survey is
manageable.
Step 2: prioritisation of outcomes
Stakeholder involvement
Stakeholder groups representing health care professionals,
people with type 2 diabetes, researchers in the field and pol-
icy makers will be invited to participate in the consensus
process (two-round online Delphi survey and face-to-face
consensus meeting) (Table 2).
People with type 2 diabetes may be older with limited
access to an online survey. At the time of registration
participants will be asked which 10-year age bracket they
Fig. 1 Overview of COS development process
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fall into. The number of participants in each age range
will be monitored to ensure representativeness of the
population.
We propose to contact potential participants via national
and international professional bodies and patient organisa-
tions; these may include but are not limited to those
described in Additional file 1.
Step 3: online Delphi survey
A list of outcomes identified from the sources described
in step 1 will be prioritised in a two-round online Delphi
survey. The Delphi method allows anonymous review and
scoring of outcomes in a way that gives equal influence to
all who participate, avoids an individual participant being
overtly influenced by the opinions of any other partici-
pant, facilitates international contribution and, as there is
no direct contact between participants, provides a mech-
anism for reconciling different opinions [27–29].
Outcomes will be categorised using the outcomes tax-
onomy developed by Dodd et al. [26]. The outcomes list
will be presented grouped into the core areas of death,
physiological or clinical, life impact, resource use or
adverse events. The list will then be ordered within these
domains according to the 38 categories within the
taxonomy.
Participants of the Delphi will be asked to score each
outcome using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) nine-point
Likert scale [30]. In the Delphi process the scale will be
presented in the format 1 to 9, with 1 to 3 labelled “not
important”, 4 to 6 labelled “important but not critical” and
7 to 9 labelled “critical”. An option of “unable to score”
will also be included together with an option to add a
comment to each outcome. All outcomes will be written
in plain language and the descriptions used reviewed and
contributed to by members of the SSC, including public
contributors, and the same descriptions used for all
stakeholders. Participants may also add any additional
outcomes they think important but not already included
on the list. Any additional outcomes suggested will be
reviewed by two members of the study team and new out-
comes agreed on by the SSC.
In the second round of the online Delphi survey,
responses for each stakeholder group will be summarised
for each outcome and displayed graphically as the per-
centage of each stakeholder group who has given each
score. All outcomes scored in round 1 will be carried
forward to round 2. Participants will be able to view the
grouped responses together with their own score in round
Table 1 MEDLINE search strategy
Multi-field search
(type 2 diabetes OR type II diabetes) Abstract
AND patient* Abstract
AND (Qualitative OR Themes) Abstract
AND (symptom OR treatment OR living with) Abstract
NOT (co-morbid* OR foot ulcer* OR retinopathy
OR nephropathy OR bariatric surgery OR
non-alcoholic fatty liver disease OR
cardiovascular disease)
Abstract
Table 2 Summary of stakeholders
Key stakeholder group Stakeholder grouping for presentation of
round 1 results in round 2 of the Delphi
survey
Question participants asked to consider in the
online Delphi
People with type 2 diabetes People with type 2 diabetes
and their carers
“What sorts of changes in your diabetes
management, symptoms or your day-to-day
life would tell you that a treatment was actually
helping you and what would be important in
helping you decide if it’s not?”
Carers of someone with type
2 diabetes
Health care professionals treating









Health care professionals “When treating patients with type 2 diabetes,
what results of treatment do you consider to
be the most important?”
Researchers in the field of type
2 diabetes
Researchers “When treating patients with type 2 diabetes,
what results of treatment do you consider to
be the most important?”
Health care policy makers
(Health Technology Assessment
representatives)
Health care policy makers
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1 and will be asked to re-score the outcome based on this
information using the same 1–9 scale. Participants may
choose to change their score or to keep it the same. New
outcomes identified from free text responses in round 1
will be presented in round 2 alongside the verbatim text
that led to the outcome. Participants will be asked to score
these new outcomes without reflection. Round 2 re-
sponses will be analysed using descriptive statistics and
summarised according to a predefined definition of con-
sensus (Table 3).
All rounds of the Delphi will be delivered online using
bespoke web-based Delphi software (DelphiManager)
designed, hosted and delivered by the University of
Liverpool. Registration for participation in the survey will
include specific consent questions. Completion of the sur-
vey will then be considered to imply informed consent.
Step 4: consensus meeting
The final step in the consensus process will be a
face-to-face consensus meeting to discuss the results of
the online Delphi survey and ratify the COS. The meeting
will be chaired by an independent facilitator. Participants
of the Delphi who have completing both rounds and who
express an interest in attending will be randomly selected
to attend to ensure that there are similar numbers from
each stakeholder group. Results of the two-round Delphi
will be presented as outcomes meeting the definition of
consensus (Table 3) [27]. Where outcomes have reached
consensus in or consensus out during the Delphi, partici-
pants will have the opportunity to voice opinion should
they disagree with inclusion/exclusion of the outcome in
the COS. Participants raising an objection will be invited
to provide further information before all participants of
the consensus meeting to re-score the outcome. Where
outcomes have not reached consensus during the Delphi,
they will be discussed and participants of the consensus
meeting invited to re-score the outcome.
Ethical considerations
The COS process will generate generalisable findings that
can be extrapolated from the present study to a broader
population, and therefore ethical approval has been sought
from the University of Liverpool Ethics Committee prior
to undertaking the consensus methods (online Delphi and
consensus meeting) ref.: 3306.
Discussion
There is currently no published COS for type 2 diabetes.
The development of a COS in this clinical area aims to
improve the interpretation and comparison of future
studies and reduce the risk of outcome reporting bias
and heterogeneity across studies. The SCORE-IT study
will involve multiple key stakeholder groups to ensure
that the COS is suitable and well accepted in future
research.
Study status
The SCORE-IT study is ongoing with the consensus
meeting expected to be completed in December 2018.
Additional file
Additional file 1: Summary of organisations that will be approached to
identify participants. (DOCX 15 kb)
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Table 3 Definition of consensus
Consensus classification Description Definition
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in the core outcome set
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